Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary … Read more
Medicure Inc (MCUJF) - Net Assets
Latest net assets as of September 2025: $17.31 Million USD
Based on the latest financial reports, Medicure Inc (MCUJF) has net assets worth $17.31 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($26.72 Million) and total liabilities ($9.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $17.31 Million |
| % of Total Assets | 64.77% |
| Annual Growth Rate | 7.27% |
| 5-Year Change | 8.52% |
| 10-Year Change | 365.71% |
| Growth Volatility | 220.57 |
Medicure Inc - Net Assets Trend (2000–2024)
This chart illustrates how Medicure Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medicure Inc (2000–2024)
The table below shows the annual net assets of Medicure Inc from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $20.78 Million | +4.43% |
| 2023-12-31 | $19.90 Million | -5.28% |
| 2022-12-31 | $21.00 Million | +14.09% |
| 2021-12-31 | $18.41 Million | -3.84% |
| 2020-12-31 | $19.15 Million | -28.94% |
| 2019-12-31 | $26.94 Million | -67.77% |
| 2018-12-31 | $83.59 Million | +3.57% |
| 2017-12-31 | $80.71 Million | +107.17% |
| 2016-12-31 | $38.96 Million | +773.21% |
| 2015-12-31 | $4.46 Million | +214.08% |
| 2014-12-31 | $-3.91 Million | +9.61% |
| 2013-12-31 | $-4.33 Million | -137.64% |
| 2012-12-31 | $-1.82 Million | -216.65% |
| 2011-12-31 | $-574.99K | +97.70% |
| 2010-12-31 | $-24.96 Million | -15.82% |
| 2009-12-31 | $-21.55 Million | -228.68% |
| 2008-12-31 | $-6.56 Million | -135.49% |
| 2007-12-31 | $18.48 Million | -50.29% |
| 2006-12-31 | $37.17 Million | +406.39% |
| 2005-12-31 | $7.34 Million | -65.97% |
| 2004-12-31 | $21.57 Million | +336.42% |
| 2003-12-31 | $4.94 Million | -45.01% |
| 2002-12-31 | $8.99 Million | 0.00% |
| 2001-12-31 | $8.99 Million | +133.31% |
| 2000-12-31 | $3.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medicure Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6229427900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $81.01 Million | 389.90% |
| Other Comprehensive Income | $-4.26 Million | -20.52% |
| Other Components | $10.92 Million | 52.55% |
| Total Equity | $20.78 Million | 100.00% |
Medicure Inc Competitors by Market Cap
The table below lists competitors of Medicure Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ESKER (EKE.SG)
STU:EKE
|
$2.54 Million |
|
Chase Packaging Corp
PINK:WHLT
|
$2.54 Million |
|
1000MERCIS INH. EO-10
F:2PL
|
$2.54 Million |
|
CCH Holdings Ltd Ordinary Shares
NASDAQ:CCHH
|
$2.54 Million |
|
Rincon Resources Ltd
AU:RCR
|
$2.54 Million |
|
CHINA FORTUNE HLDG.HD001
F:FTQ0
|
$2.54 Million |
|
Linus Digital Finance AG
XETRA:LDF
|
$2.54 Million |
|
Uni-Fuels Holdings Limited Class A Ordinary Shares
NASDAQ:UFG
|
$2.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medicure Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,896,000 to 20,778,000, a change of 882,000 (4.4%).
- Net loss of 1,039,000 reduced equity.
- Other comprehensive income increased equity by 1,725,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.04 Million | -5.0% |
| Other Comprehensive Income | $1.73 Million | +8.3% |
| Other Changes | $196.00K | +0.94% |
| Total Change | $- | 4.43% |
Book Value vs Market Value Analysis
This analysis compares Medicure Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.24x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.13x to 0.24x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $3.58 | $0.48 | x |
| 2001-12-31 | $4.87 | $0.48 | x |
| 2002-12-31 | $4.87 | $0.48 | x |
| 2003-12-31 | $1.97 | $0.48 | x |
| 2004-12-31 | $5.80 | $0.48 | x |
| 2005-12-31 | $1.65 | $0.48 | x |
| 2006-12-31 | $7.42 | $0.48 | x |
| 2007-12-31 | $2.64 | $0.48 | x |
| 2008-12-31 | $-0.78 | $0.48 | x |
| 2009-12-31 | $-2.48 | $0.48 | x |
| 2010-12-31 | $-2.87 | $0.48 | x |
| 2011-12-31 | $-0.07 | $0.48 | x |
| 2012-12-31 | $-0.15 | $0.48 | x |
| 2013-12-31 | $-0.35 | $0.48 | x |
| 2014-12-31 | $-0.32 | $0.48 | x |
| 2015-12-31 | $0.28 | $0.48 | x |
| 2016-12-31 | $2.13 | $0.48 | x |
| 2017-12-31 | $4.45 | $0.48 | x |
| 2018-12-31 | $5.05 | $0.48 | x |
| 2019-12-31 | $1.80 | $0.48 | x |
| 2020-12-31 | $1.79 | $0.48 | x |
| 2021-12-31 | $1.80 | $0.48 | x |
| 2022-12-31 | $2.01 | $0.48 | x |
| 2023-12-31 | $1.91 | $0.48 | x |
| 2024-12-31 | $1.99 | $0.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medicure Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.74%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 1.43x
- Recent ROE (-5.00%) is above the historical average (-25.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -83.91% | -2378.79% | 0.03x | 1.15x | $-3.62 Million |
| 2001 | -43.12% | -2107.03% | 0.02x | 1.04x | $-4.77 Million |
| 2002 | -43.12% | -2107.03% | 0.02x | 1.04x | $-4.77 Million |
| 2003 | -84.86% | -1738.09% | 0.05x | 1.07x | $-4.69 Million |
| 2004 | -27.77% | -1344.47% | 0.02x | 1.04x | $-8.15 Million |
| 2005 | -202.53% | -3237.37% | 0.05x | 1.37x | $-15.60 Million |
| 2006 | -33.92% | -4206.05% | 0.01x | 1.04x | $-16.32 Million |
| 2007 | -171.60% | -533.30% | 0.09x | 3.46x | $-33.55 Million |
| 2008 | 0.00% | -2554.48% | 0.06x | 0.00x | $-56.75 Million |
| 2009 | 0.00% | -277.85% | 0.61x | 0.00x | $-11.16 Million |
| 2010 | 0.00% | -166.79% | 0.56x | 0.00x | $-3.04 Million |
| 2011 | 0.00% | -55.51% | 0.56x | 0.00x | $-1.96 Million |
| 2012 | 0.00% | 487.53% | 1.01x | 0.00x | $23.57 Million |
| 2013 | 0.00% | -98.91% | 0.76x | 0.00x | $-2.14 Million |
| 2014 | 0.00% | -32.45% | 0.77x | 0.00x | $-1.25 Million |
| 2015 | 37.40% | 7.56% | 1.04x | 4.76x | $1.22 Million |
| 2016 | 75.02% | 73.21% | 0.18x | 5.82x | $23.97 Million |
| 2017 | 53.80% | 160.03% | 0.21x | 1.60x | $35.35 Million |
| 2018 | 4.70% | 13.49% | 0.28x | 1.24x | $-4.43 Million |
| 2019 | -73.44% | -98.08% | 0.48x | 1.57x | $-22.48 Million |
| 2020 | -36.01% | -59.38% | 0.34x | 1.78x | $-8.81 Million |
| 2021 | -3.95% | -3.34% | 0.77x | 1.54x | $-2.57 Million |
| 2022 | 6.50% | 5.92% | 0.77x | 1.42x | $-735.50K |
| 2023 | -4.63% | -4.25% | 0.77x | 1.41x | $-2.91 Million |
| 2024 | -5.00% | -4.74% | 0.74x | 1.43x | $-3.12 Million |
Industry Comparison
This section compares Medicure Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medicure Inc (MCUJF) | $17.31 Million | -83.91% | 0.54x | $2.54 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |